T1	Participants 90 130	patients with primary biliary cirrhosis.
T2	Participants 235 275	patients with primary biliary cirrhosis.
T3	Participants 803 852	32 patients (18 ursodeoxycholic acid, 14 placebo)
T4	Participants 967 981	placebo group.
